[go: up one dir, main page]

AR119056A2 - Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada - Google Patents

Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada

Info

Publication number
AR119056A2
AR119056A2 ARP200101538A ARP200101538A AR119056A2 AR 119056 A2 AR119056 A2 AR 119056A2 AR P200101538 A ARP200101538 A AR P200101538A AR P200101538 A ARP200101538 A AR P200101538A AR 119056 A2 AR119056 A2 AR 119056A2
Authority
AR
Argentina
Prior art keywords
vector
transformed cell
fusion peptide
encoding polynucleotide
isoform
Prior art date
Application number
ARP200101538A
Other languages
English (en)
Inventor
Ricardo Alfredo Dewey
Zamora Benito Jorge Velasco
Tania Melina Rodriguez
Alejandra Carrea
Andrea Nancy CHISARI
Marcelo Javier Perone
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Fund Articular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Fund Articular filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of AR119056A2 publication Critical patent/AR119056A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una isoforma del receptor II de TGFb que comprende una secuencia de alrededor de 80 aminoácidos y carece del dominio transmembrana; en donde la isoforma es agonista de TGFb-1. La isoforma comprende a la secuencia de aminoácidos SEQ ID Nº 12. La isoforma puede tener la secuencia de aminoácidos SEQ ID Nº 2 o secuencias que tienen al menos un 85% de identidad de secuencia con la secuencia SEQ ID Nº 2.
ARP200101538A 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada AR119056A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917974P 2013-12-19 2013-12-19

Publications (1)

Publication Number Publication Date
AR119056A2 true AR119056A2 (es) 2021-11-17

Family

ID=53403721

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
ARP200101538A AR119056A2 (es) 2013-12-19 2020-05-29 Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
ARP240101109A AR132574A2 (es) 2013-12-19 2024-05-02 UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104755A AR098827A1 (es) 2013-12-19 2014-12-18 ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP240101109A AR132574A2 (es) 2013-12-19 2024-05-02 UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA

Country Status (5)

Country Link
US (1) US10233227B2 (es)
EP (1) EP3082846B1 (es)
AR (3) AR098827A1 (es)
ES (1) ES2749615T3 (es)
WO (1) WO2015095628A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107780A1 (es) * 2016-11-14 2018-06-06 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Método para determinar la actividad de enfermedades autoinmunes y kit
JP7319992B2 (ja) 2018-03-09 2023-08-02 アジェナス インコーポレイテッド 抗ｃｄ７３抗体およびそれらの使用方法
CN110372800B (zh) 2019-08-27 2022-06-07 南京安吉生物科技有限公司 具有多功能活性的融合多肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1994009815A1 (en) 1992-10-29 1994-05-11 Celtrix Pharmaceuticals, Inc. USES OF TGF-β RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030028905A1 (en) * 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
WO2003060075A2 (en) 2001-12-21 2003-07-24 The Regents Of The University Of California USE OF SOLUBLE TYPE II TGF-β RECEPTOR TO SUPPRESS PANCREATIC CANCER GROWTH AND METASTASIS
JP2010529859A (ja) 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途

Also Published As

Publication number Publication date
US10233227B2 (en) 2019-03-19
US20160318989A1 (en) 2016-11-03
WO2015095628A8 (en) 2016-09-29
EP3082846A1 (en) 2016-10-26
AR132574A2 (es) 2025-07-16
AR098827A1 (es) 2016-06-15
WO2015095628A1 (en) 2015-06-25
EP3082846B1 (en) 2019-07-17
ES2749615T3 (es) 2020-03-23
EP3082846A4 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
ES2545895T3 (es) Proteína de fusión anticancerígena
AR132574A2 (es) UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA
EA201491049A1 (ru) Противораковый слитый белок
CL2017001070A1 (es) Variantes de interferon a2b
NZ731571A (en) T cell receptors
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EA201691111A1 (ru) Химерные белки фактора viii и их применение
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
EA201491277A1 (ru) Противораковый слитый белок
EA201270517A1 (ru) Микобактериальные вакцины
UA118167C2 (uk) Пептид та його застосування
CY1119916T1 (el) Ανοσογονικη συνθεση
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX391266B (es) Variantes de hppd y metodos de uso.
ES2671434T3 (es) Antagonistas de Kv1.3 y métodos de uso
NZ706884A (en) Fc gamma receptor iib variants
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
MX364732B (es) Vacuna contra el tumor de wilms 1.
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии